PENPULIMAB-KCQX
Clinical safety rating
cautionComprehensive clinical and safety monograph for PENPULIMAB-KCQX (PENPULIMAB-KCQX).
Comprehensive clinical and safety monograph for PENPULIMAB-KCQX (PENPULIMAB-KCQX).
Unresectable or metastatic hepatocellular carcinoma (HCC) in patients who have not received prior systemic therapy
Penpulimab-kcqx is a humanized monoclonal antibody that binds to programmed death-1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2, thereby releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
| Metabolism | Penpulimab-kcqx is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via general protein catabolism. |
| Excretion | Pembrolizumab is a humanized monoclonal antibody (IgG4) that undergoes catabolism via the reticuloendothelial system (RES) to small peptides and amino acids; no renal or biliary excretion of intact antibody occurs. Elimination pathways (%): catabolism (100%), unchanged renal excretion (<1%), unchanged biliary/fecal excretion (<1%). |
| Half-life | Terminal elimination half-life is approximately 22 days (range: 15–27 days) in patients receiving 2 mg/kg or 200 mg every 3 weeks. This long half-life supports every-3-week dosing. Clearance decreases over time due to target-mediated drug disposition and saturable binding to PD-1 receptors. |
| Protein binding | Pembrolizumab is not bound to plasma proteins (0% protein binding). As a monoclonal antibody, it circulates freely in plasma. |
| Volume of Distribution | Vd is approximately 0.06 L/kg (range: 0.04–0.08 L/kg) in adults, indicating limited extravascular distribution consistent with a large IgG antibody that remains primarily in the intravascular space (about 6 L in a 70 kg adult). |
| Bioavailability | Pembrolizumab is administered only intravenously; bioavailability is 100% by IV route. No oral or subcutaneous formulation is approved. Subcutaneous bioavailability is not determined. |
| Onset of Action | In patients with advanced melanoma or NSCLC, clinical response may be observed as early as 8–12 weeks after the first dose. However, some responses occur later (e.g., after 6 months). True onset of pharmacodynamic effect (PD-1 blockade) occurs within hours of infusion, but tumor regression requires immune activation time. |
| Duration of Action | Duration of PD-1 receptor occupancy on peripheral T cells persists for several weeks to months after a single dose. Clinically, treatment continues until disease progression or unacceptable toxicity, typically for 2 years (35 cycles) with response lasting a median of 12–24 months in responders. |
| Molecular Weight | 146 kDa |
200 mg intravenously over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not recommended in moderate or severe hepatic impairment (Child-Pugh B or C) due to lack of data. |
| Pediatric use | Safety and efficacy not established in pediatric patients. No recommended dose. |
| Geriatric use | No specific dose adjustment required; geriatric patients in clinical studies received the same dose as younger adults. Monitor for increased adverse reactions. |
| 1st trimester | No human data; based on mechanism, may cause fetal harm due to targeting of immune checkpoints; consider risk-benefit. |
| 2nd trimester | No human data; potential for increased risk of fetal loss or immune-mediated disorders; avoid unless benefit outweighs risk. |
| 3rd trimester | No human data; human IgG crosses placenta; potential for neonatal immune suppression; avoid in third trimester. |
Clinical note
Comprehensive clinical and safety monograph for PENPULIMAB-KCQX (PENPULIMAB-KCQX).
| Placental transfer | Human IgG4 monoclonal antibody; known to cross placenta; degree increases as pregnancy advances, especially in third trimester. |
| Breastfeeding | No data on presence in human milk; potential for adverse effects in breastfed infant; weigh benefits against risks; consider use of alternative therapies. |
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | PENPULIMAB-KCQX is a human IgG4 monoclonal antibody. IgG molecules are actively transported across the placenta during the third trimester. Based on its mechanism of action (PD-1 blockade), there is a potential risk of immune-mediated fetal harm including increased rates of abortion, stillbirth, and neonatal death, as observed in animal models. Human data are limited. Use during pregnancy should be avoided unless the potential benefit outweighs the risk. There is no known risk specifically by trimester, but the greatest transfer occurs after 30 weeks gestation. |
| Fetal Monitoring | Monitor maternal and fetal status during pregnancy. In women of reproductive potential, verify pregnancy status prior to initiation. Perform fetal ultrasonography if exposure occurs during pregnancy. Monitor for signs of immune-mediated adverse reactions in the newborn, including hypothyroidism, pneumonitis, colitis, hepatitis, and endocrinopathies. |
| Fertility Effects | Based on animal studies, PENPULIMAB-KCQX may impair female fertility. Administration in female cynomolgus monkeys resulted in menstrual cycle irregularities and reduced fertility at exposures similar to clinical doses. Effects on male fertility have not been adequately studied, but PD-1 pathway blockade may affect reproductive function. Advise patients of potential risk. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to pembrolizumab or any excipients
| Precautions | Immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and dermatologic reactions, Infusion-related reactions, Embryo-fetal toxicity |
| Food/Dietary | No known food interactions. Avoid grapefruit juice if co-administered with CYP3A4 substrates. Maintain adequate hydration. |
| Clinical Pearls | Administer intravenous infusion over 30 minutes. Premedicate with antihistamines and antipyretics to reduce infusion-related reactions. Monitor for immune-related adverse effects, particularly pneumonitis, colitis, hepatitis, and endocrinopathies. Do not mix with other drugs in the same infusion line. Use 5% dextrose in water or 0.9% sodium chloride for dilution. |
| Patient Advice | Report any new or worsening cough, chest pain, or shortness of breath immediately. · Notify your healthcare provider if you experience diarrhea, abdominal pain, or blood in stool. · Watch for signs of hepatitis: yellowing of skin or eyes, dark urine, severe nausea or vomiting, or bleeding/bruising. · Inform your doctor if you develop severe fatigue, weight gain or loss, hair thinning, depression, or changes in heart rate. · Use effective contraception during treatment and for at least 4 months after the last dose. |
Loading safety data…